Product image of Irinotecan Eugia (Irinotecan Hydrochloride Trihydrate) supplied by GNH India

Irinotecan Eugia

Active Ingredient:
Irinotecan Hydrochloride Trihydrate
Origin:
EU

Irinotecan Eugia (Irinotecan Hydrochloride Trihydrate)

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Eugia, is a topoisomerase I inhibitor presented as a sterile injectable solution for intravenous use. It is employed in the treatment of colorectal cancer, primarily in adult patients requiring systemic chemotherapy, and is commonly used within combination regimens such as FOLFIRI under the supervision of qualified healthcare professionals.

GNH India supplies Irinotecan Eugia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and procurement teams worldwide, ensuring quality‑assured product availability and regulatory compliance.

Manufacturer / TM Owner

Eugia Pharma (Malta) Ltd

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Irinotecan Eugia is a topoisomerase I inhibitor used in colorectal cancer chemotherapy.
  • Colorectal cancer (adjuvant setting): improves disease‑free survival when added to postoperative chemotherapy.
  • Metastatic colorectal cancer (first‑line): forms part of combination regimens to reduce tumor burden.
  • Metastatic colorectal cancer (second‑line): provides an alternative after progression on oxaliplatin‑based therapy.

How It Works

  • Irinotecan is converted intracellularly to its active metabolite SN‑38, which binds to the DNA‑topoisomerase I complex and stabilizes it, preventing the re‑ligation of single‑strand DNA breaks during replication. This inhibition leads to accumulation of DNA damage, triggering apoptosis in rapidly dividing tumor cells. The drug is primarily eliminated by hepatic glucuronidation via UGT1A1, and genetic variations in this enzyme can affect exposure and toxicity.

Side Effects

Irinotecan Eugia may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Diarrhea: often delayed and may be severe.
  • Neutropenia: reduced white blood cell count.
  • Nausea and vomiting.
  • Fatigue: general tiredness.

Serious or Rare Side Effects

  • Febrile neutropenia: fever with low neutrophils.
  • Life‑threatening diarrhea (colitis) leading to dehydration.
  • Cholinergic syndrome: sweating, bradycardia, bronchospasm.
  • Hypersensitivity reactions: rash, anaphylaxis.

Precautions & Warnings

When using Irinotecan Eugia, several precautions should be observed to minimize risks and ensure safe administration.

  • Monitor blood counts: perform regular CBC to detect neutropenia.
  • Assess liver function: adjust dose in hepatic impairment.
  • Maintain hydration: adequate fluids reduce severity of diarrhea.
  • Avoid strong UGT1A1 inhibitors: drugs like atazanavir may increase toxicity.
  • Pregnancy and lactation: use only if potential benefit justifies risk.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Irinotecan Eugia can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

  • Strong UGT1A1 inhibitors (e.g., atazanavir, indinavir): increase SN‑38 exposure.
  • CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): raise plasma levels.
  • Concurrent myelosuppressive agents: heightened risk of severe neutropenia.
  • Anticholinergic drugs: may exacerbate cholinergic syndrome.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inducers (e.g., rifampin, St. John’s wort): may reduce effectiveness.
  • Warfarin: monitor INR as irinotecan may affect coagulation.
  • NSAIDs: increase risk of gastrointestinal toxicity.

Frequently Asked Questions

Irinotecan Eugia contains the cytotoxic agent irinotecan hydrochloride tri­hydrate and is used in oncology as part of chemotherapy regimens for patients with colorectal cancer, including both adjuvant and metastatic settings. It works by interfering with DNA replication in rapidly dividing tumor cells.

The drug is converted inside cells to the active metabolite SN‑38, which binds to the DNA‑topoisomerase I complex and prevents the re‑ligation of single‑strand DNA breaks during replication. This leads to accumulation of DNA damage and triggers apoptosis of cancer cells.

The prescribed dose of Irinotecan Eugia is determined by the treating oncologist based on factors such as the patient’s body surface area, disease stage, prior therapies and organ function. The healthcare professional sets the exact dosing schedule and infusion rate.

Safety data for Irinotecan in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and breastfeeding is generally discouraged during treatment.

To place an order, submit an enquiry on the Irinotecan Eugia product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Irinotecan belongs to the topoisomerase I inhibitor class, whereas alternatives such as oxaliplatin are platinum‑based agents. Both are used in combination regimens, but they differ in toxicity profiles; irinotecan is more associated with diarrhea and neutropenia, while oxaliplatin commonly causes peripheral neuropathy.

Irinotecan Eugia should be stored refrigerated at 2 °C to 8 °C, protected from light, and must not be frozen or shaken. The product should be kept in its original packaging until ready for preparation and administration.

The medication is supplied as a sterile injectable solution for intravenous infusion. It is administered by a qualified healthcare professional, typically as an infusion over 30 to 90 minutes, according to the dosing schedule prescribed by the oncologist.

The most severe adverse events include febrile neutropenia, life‑threatening delayed diarrhea (colitis), cholinergic syndrome, and severe hypersensitivity reactions. Prompt recognition and supportive care are essential to manage these risks.

Patients with known hypersensitivity to irinotecan or any of its excipients, those with severe hepatic impairment, and individuals with uncontrolled infections or active bowel obstruction should avoid Irinotecan Eugia. The prescribing clinician must evaluate each patient’s suitability before initiating therapy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Irinotecan Hydrochloride Trihydrate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT